spironolactone has been researched along with Coronary Vasospasm in 10 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Coronary Vasospasm: Spasm of the large- or medium-sized coronary arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both renal denervation (RDN) and spironolactone have been proposed for the treatment of resistant hypertension." | 9.22 | Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. ( Armario, P; Clarà, A; De la Sierra, A; Oliveras, A; Pascual, J; Sans-Atxer, L; Vázquez, S, 2016) |
| "Aldosterone excretion was determined by 24 h urine (24h-UAldo) collected at randomization and after 6 months of follow-up." | 6.84 | Effects of continuous positive airway pressure treatment on aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension: a randomized controlled trial. ( Cavalcanti, AH; Cortez, AF; de Souza, F; Margallo, V; Muxfeldt, ES; Salles, GF, 2017) |
| "The randomized, multicentre study compared the efficacy of renal denervation (RDN) versus spironolactone addition in patients with true resistant hypertension." | 5.24 | Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. ( Bednář, F; Branny, M; Čurila, K; Holaj, R; Indra, T; Jiravský, O; Kociánová, E; Krátká, Z; Lambert, L; Nykl, I; Petrák, O; Rappová, G; Rosa, J; Štrauch, B; Táborský, M; Toušek, P; Václavík, J; Waldauf, P; Widimský, J; Widimský, P; Zelinka, T, 2017) |
| "Both renal denervation (RDN) and spironolactone have been proposed for the treatment of resistant hypertension." | 5.22 | Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. ( Armario, P; Clarà, A; De la Sierra, A; Oliveras, A; Pascual, J; Sans-Atxer, L; Vázquez, S, 2016) |
| "Aldosterone excretion was determined by 24 h urine (24h-UAldo) collected at randomization and after 6 months of follow-up." | 2.84 | Effects of continuous positive airway pressure treatment on aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension: a randomized controlled trial. ( Cavalcanti, AH; Cortez, AF; de Souza, F; Margallo, V; Muxfeldt, ES; Salles, GF, 2017) |
| "Resistant hypertension is defined as a lack of ambulatory blood pressure response to optimized medical treatment after exclusion of secondary hypertension in patients who are fully adherent to antihypertensive therapy." | 2.58 | Diagnosis and management of resistant hypertension: state of the art. ( Huang, QF; Staessen, JA; Wei, FF; Zhang, ZY, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, FF | 1 |
| Zhang, ZY | 1 |
| Huang, QF | 1 |
| Staessen, JA | 1 |
| Riester, A | 1 |
| Reincke, M | 1 |
| Beuschlein, F | 1 |
| Overbeck, P | 1 |
| Holzgreve, H | 1 |
| Oliveras, A | 1 |
| Armario, P | 1 |
| Clarà, A | 1 |
| Sans-Atxer, L | 1 |
| Vázquez, S | 1 |
| Pascual, J | 1 |
| De la Sierra, A | 1 |
| Schneider, A | 2 |
| Schwab, J | 1 |
| Karg, MV | 1 |
| Kalizki, T | 2 |
| Reinold, A | 2 |
| Schneider, MP | 2 |
| Schmieder, RE | 2 |
| Schmidt, BM | 1 |
| Rosa, J | 1 |
| Widimský, P | 1 |
| Waldauf, P | 1 |
| Zelinka, T | 1 |
| Petrák, O | 1 |
| Táborský, M | 1 |
| Branny, M | 1 |
| Toušek, P | 1 |
| Čurila, K | 1 |
| Lambert, L | 1 |
| Bednář, F | 1 |
| Holaj, R | 1 |
| Štrauch, B | 1 |
| Václavík, J | 1 |
| Kociánová, E | 1 |
| Nykl, I | 1 |
| Jiravský, O | 1 |
| Rappová, G | 1 |
| Indra, T | 1 |
| Krátká, Z | 1 |
| Widimský, J | 1 |
| de Souza, F | 1 |
| Muxfeldt, ES | 1 |
| Margallo, V | 1 |
| Cortez, AF | 1 |
| Cavalcanti, AH | 1 |
| Salles, GF | 1 |
| Schmidt, BMW | 1 |
| Raff, U | 1 |
| Schwarz, TK | 1 |
| Bendersky, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sympathetic Renal Denervation Versus Increment of Pharmacological Treatment in Resistant Arterial Hypertension[NCT02039492] | 38 participants (Actual) | Interventional | 2012-09-30 | Completed | |||
| Efficacy of Continuous Positive Airway Pressure (CPAP) on Blood Pressure Control of Resistant Hypertension Patients With Obstructive Sleep Apnea Syndrome (OSAS).[NCT01508754] | Phase 4 | 125 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for spironolactone and Coronary Vasospasm
| Article | Year |
|---|---|
Diagnosis and management of resistant hypertension: state of the art.
Topics: Amiloride; Animals; Antihypertensive Agents; Arteriovenous Shunt, Surgical; Baroreflex; Blood Pressu | 2018 |
[Primary hyperaldosteronism: boundaries of diagnostics and therapy].
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Adrenocortical Hyperfunction; Aldos | 2014 |
[Aldosterone antagonists--first choice in resistant hypertension].
Topics: Adrenergic beta-Antagonists; Coronary Vasospasm; Diuretics, Potassium Sparing; Drug Therapy, Combina | 2016 |
[Resistant hypertension].
Topics: Age Factors; Aldosterone; Coronary Vasospasm; Disease Management; Diuretics; Humans; Hyperaldosteron | 2012 |
6 trials available for spironolactone and Coronary Vasospasm
| Article | Year |
|---|---|
[Spironolactone is the best option in "resistant" hypertension].
Topics: Antihypertensive Agents; Coronary Vasospasm; Humans; Hypertension; Spironolactone | 2015 |
Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Coronary Vasos | 2016 |
Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Coronary Vasospasm; Double-Blind Method; Drug Therapy | 2017 |
Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Coronar | 2017 |
Effects of continuous positive airway pressure treatment on aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension: a randomized controlled trial.
Topics: Aged; Aldosterone; Continuous Positive Airway Pressure; Coronary Vasospasm; Diuretics; Female; Follo | 2017 |
Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension.
Topics: Aged; Blood Pressure Determination; Carotid Intima-Media Thickness; Coronary Vasospasm; Double-Blind | 2017 |